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Abstract	
The	 fracture	 impact	of	 adjuvant	bisphosphonates	 in	breast	 cancer	 is	 not	defined	with	
most	 trials	 reporting	changes	 in	bone	mineral	density	as	a	surrogate.	 	The	AZURE	trial	
(ISRCTN79831382) evaluated	the	impact	of	adjuvant	zoledronic	acid	(ZOL)	on	fractures.	
The	AZURE	trial	is	an	academic,	multi-centre,	randomised	phase	III	study	evaluating	the	
addition	 of	 ZOL	 4mg	 to	 standard	 therapy	 (neo/adjuvant	 chemotherapy	 and/or	
endocrine	 therapy)	 for	 5	 years	 (administered	 by	 intravenous	 (iv)	 infusion	 every	 3-4	
weeks	 for	6	doses,	 then	3	monthly	x	8	and	6	monthly	x	5)	 in	patients	with	 stage	 II/III	
early	 breast	 cancer.	 	 Fracture	 data	 collected	 as	 part	 of	 skeletal	 related	 adverse	 event	
reporting	were	analysed	after	 a	median	of	 84.2	months	of	 follow	up	 and	966	disease	
free	survival	 (DFS)	events.	We	assessed	number	of	 fractures,	time	to	first	 fracture	and	
the	incidence	of	fractures	before	and	after	disease	recurrence.	
244	patients	reported	≥1	fracture,	140	(8.3%)	in	the	control	arm	(171	fractures)	and	104	
(6.2%)	 in	 the	 ZOL	 arm	 (120	 fractures).	 Of	 the	 291	 fractures	 reported,	 207	 fractures	
occurred	 in	 the	 absence	 of	 recurrence	 (Control	 111,	 ZOL	 96),	 80	 after	 recurrence	
(Control	59,	ZOL	21).		The	5-year	fracture	rate	was	reduced	from	5.9%	(95%CI	4.8,	7.1%)	
(control)	 to	 3.8%	 (95%CI	 2.9,	 4.7%)	with	 ZOL.	 ZOL	 significantly	 increased	 time	 to	 first	
fracture	 (HR	0.69,	95%	CI	0.53-0.90	p=0.0053)	but	 the	majority	of	 fracture	prevention	
benefit	occurred	after	a	DFS	event	(HR	0.3;	95%CI	0.17,	0.53	P<0.001).	Fracture	benefits	
from	ZOL	were	similar	across	menopausal	sub-groups.		
In	conclusion,	adjuvant	zoledronic	acid	reduced	the	risk	of	clinical	fractures,	the	majority	
of	this	protection	occurred	after	disease	recurrence.		
	
Key	words;	adjuvant,	zoledronic	acid,	fractures,	breast	cancer.	
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Introduction	
Adjuvant	 chemotherapy	 and	 endocrine	 treatments	 are	 an	 integral	 part	 of	 the	 multi-
modality	 management	 of	 early	 breast	 cancer	 used	 to	 reduce	 the	 risk	 of	 disease	
recurrence	 and	mortality.	However,	 these	 therapies	 result	 in	 bone	 loss,	 either	 due	 to	
the	direct	effect	on	the	balance	of	bone	formation	by	osteoblasts	and	bone	resorption	
by	 osteoclasts,	 or	 due	 to	 indirect	 effects	 of	 lowering	 systemic	 oestrogen	 (ovarian	
failure/suppression	 in	 premenopausal	 patients	 and	 aromatase	 inhibitors	 (AIs)	 in	
postmenopausal	 women)[1,2].	 A	 breast	 cancer	 diagnosis	 per	 se	 is	 associated	with	 an	
increased	 risk	of	 fracture	 in	 the	absence	of	metastatic	disease	 [3,4]	 and	 standard	 risk	
estimation	scores	(i.e.	FRAX)	underestimate	fracture	risk	[5].	Fractures	impair	quality	of	
life,	increase	health	care	costs	and	decrease	survival	[6].	
	
Because	 of	 the	 adverse	 impact	 of	 treatments	 on	 bone	 health,	 breast	 cancer	 patients	
may	 require	 intensive	 bone	 protective	management.	 Postmenopasual	 women	 have	 a	
natural	yearly	loss	in	bone	mineral	density	(BMD)	at	the	lumbar	spine	of	1%/year;	rising	
to	2%/year	in	breast	cancer	patients	receiving	AIs	and	up	to	7%/year	in	premenopausal	
patients	 with	 treatment	 induced	 ovarian	 failure	 [6].	 Bisphosphonates	 can	 prevent	
treatment	 related	bone	 loss,	with	most	data	 available	 for	 zoledronic	 acid	 (ZOL)	which	
prevents	 both	 the	 bone	 loss	 associated	with	 AIs	 and	with	 ovarian	 failure/suppression	
[7,8]
	
.		The	majority	of	adjuvant	bisphosphonate	studies,	as	bone	protective	agents,	have	
focused	on	changes	in	BMD	as	the	primary	endpoint	and	were	not	designed	to	reliably	
assess	treatment	effects	on	fracture	incidence	[9-14].			
	
The	 AZURE	 study	 is	 an	 academic,	 multi-centre,	 international	 phase	 III	 trial	 that	
randomized	 patients	 with	 early	 breast	 cancer	 to	 standard	 adjuvant	 therapy	
(chemotherapy	and/or	endocrine	therapy)	alone	or	with	the	addition	of	an	intravenous	
infusion	 of	 ZOL	 4mg	 for	 5	 years	 (administered	 every	 3-4	 weeks	 for	 6	 doses,	 then	 3	
monthly	 x	 8	 and	 6	 monthly	 x	 5).	 The	 efficacy	 data	 have	 been	 published	 previously	
[15,16]	with	disease	free	survival	(DFS)	events	showing	that,	despite	a	reduction	in	the	
risk	 of	 developing	 bone	 metastases,	 there	 was	 no	 effect	 on	 overall	 breast	 cancer	
recurrence.	However,	preplanned	subgroup	analyses	 identified	benefit	 in	women	who	
were	 in	established	menopause	at	 the	time	of	study	entry	 (n=1041,	adjusted	HR	0.77;	
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95%CI	0.63,	0.96),	an	observation	which	has	been	confirmed	by	the	Early	Breast	Cancer	
Clinical	Trials	Collaborative	Group	(EBCTCG)	meta-analysis	of	>18,000	women	 included	
in	randomized	trials	of	adjuvant	bisphosphonates.[17]			
	
The	 AZURE	 study	 also	 collected	 data	 on	 fractures	 as	 part	 of	 skeletal	 related	 event	
reporting	by	treating	clinicians	and	represents	one	of	the	largest	data	sets	for	evaluation	
of	fracture	 incidence	 in	patients	treated	+/-	ZOL	during	adjuvant	therapy.	 In	this	study	
we	 present	 the	 data	 on	 fractures,	 as	 a	 pre-planned	 secondary	 end	 point	 analysis,	 to	
assess	 the	 effects	 of	 ZOL	 on	 fractures	 pre-	 and	 post	 disease	 recurrence	 and	 the	
differential	effect	according	to	menopausal	status	at	baseline.	
	
Patients	and	methods	
Eligibility	 criteria	 have	 been	 reported	 previously
	
[15].	 	 To	 summarise,	 eligible	 patients	
had;	 histologically	 confirmed	 invasive	 breast	 cancer,	 pathologically	 involved	 axillary	
lymph	node	metastasis	or	a	T3/T4	primary	tumour,	complete	resection	of	 the	primary	
tumour	 or	 planned	 resection	 if	 receiving	 neoadjuvant	 chemotherapy,	 aged	 ≥18	 years,	
Karnofsky	performance	status	index	≥80,	not	pregnant	or	breast-feeding.	Patients	were	
ineligible	 if	 there	 was	 clinical/imaging	 evidence	 of	 distant	 metastases	 prior	 to	 study	
entry,	 current,	 recent	 (previous	 year)	 or	 intended	 use	 of	 bisphosphonates	 for	 pre-
existing	bone	disease.	
	
Between	September	2003	and	February	2006,	3360	patients	were	randomized	1:1	using	
a	 computer	 generated	 system	 which	 included	 the	 following	 minimization	 criteria;	
number	 of	 involved	 lymph	 nodes,	 clinical	 tumour	 stage,	 oestrogen	 receptor	 status,	
clinical	menopausal	status,	type	and	timing	of	systemic	therapy,	study	centre	and	statin	
use.			
	
Patients	 received	standard	adjuvant	 therapy	and	 locoregional	 treatments	according	 to	
institutional	protocols	+/-	intravenous	ZOL,	4mg	every	3	to	4	weeks	for	6	cycles	and	then	
every	3	months	for	8	doses,	followed	by	5	cycles	on	a	6-month	schedule	for	a	total	of	5	
years[15].	 	 Once	 distant	 recurrence	 was	 identified	 trial	 medication	 was	 stopped	 and	
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patients	were	 treated	 as	 per	 local	 site	 protocol.	 Ethical	 approval	was	 obtained	 for	 all	
participating	centres	and	all	patients	gave	written	informed	consent	before	enrolment.	
	
Patient	evaluation	
Fractures	were	reported	as	part	of	trial	follow-up	visits,	occurring	3-4	weekly	for	the	first	
6	 months,	 3-monthly	 to	 2.5	 years,	 6-monthly	 to	 5	 years	 and	 annually	 to	 10	 years.	
Fractures	 were	 reported	 on	 the	 case	 report	 form	 (CRF)	 as	 a	 specific	 skeletal	 related	
event	 and	 recorded	 as	 present	 or	 not,	 site(s)	 involved,	 date	 of	 onset	 and	 cause.	
Fractures	were	recorded	in	relation	to	DFS	events.	If	a	fracture	occurred	prior	to	disease	
recurrence	 the	 causality	 of	 the	 fracture	 was	 recorded	 as	 traumatic	 or	 non-traumatic	
including	 osteoporosis.	 	 Fractures	 that	 occurred	 after	 a	 DFS	 event	 were	 recorded	 as	
traumatic	or	non-traumatic	including	pathological	fracture	
	
Statistical	methods	
Statistical	 analysis	 was	 performed	 on	 the	 ‘final	 analysis’	 data[16].	 Data	 lock	 occurred	
after	 a	median	of	84.2	 (IQR	71-92)	months	of	 follow	up	and	966	disease-free	 survival	
events.	 All	 analyses	 were	 performed	 on	 the	 intention-to-treat	 population	 using	 SAS	
version	9.2	or	9.4.		
	
Cumulative	incidence	function	curves	were	used	to	investigate	time	to	first	fracture	pre-	
and	 post-DFS	 event,	 to	 account	 for	 death	 as	 a	 competing	 risk.	 Cox’s	 proportional	
hazards	 model	 was	 used	 to	 compare	 differences	 between	 the	 two	 treatment	 arms,	
adjusting	 for	 minimization	 factors.	 An	 interaction	 between	 menopausal	 status	 and	
treatment	was	included	in	the	model	when	assessing	differences	by	menopausal	status.	
	
Patients	 with	 any	 missing	 fracture	 dates	 were	 censored	 at	 the	 last	 date	 they	 were	
known	 to	be	alive	and	without	any	 fractures	 in	 the	main	analysis	 (n=19).	A	 sensitivity	
analysis	was	performed	to	 include	these	patients	as	having	had	an	event	 (taken	to	be	
the	mid-point	between	follow-up	date	at	which	the	fracture	was	reported	and	the	last	
date	the	patient	was	known	to	be	without	any	fractures).	
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Results	
Patient	characteristics	
3359	 patients	 were	 eligible	 for	 inclusion	 in	 this	 analysis	 (see	 figure	 1).	 	 Patient	
demographics	have	been	published	previously[15]	 and	 those	 relevant	 for	 this	 analysis	
are	summarised	in	table	1.	Additional	risk	factors	for	fracture	including	smoking,	alcohol,	
family	 history	 of	 osteoporosis	 and	 previous	 fragility	 fracture	 were	 not	 routinely	
recorded.	Baseline	bone	density	measurements	were	not	routinely	performed.	
	
Fracture	incidence	
244	patients	experienced	one	or	more	fractures	on	study,	140	(8.3%)	in	the	control	arm	
(171	 fractures)	 and	 104	 (6.2%)	 in	 the	 ZOL	 arm	 (120	 fractures).	 Of	 the	 291	 fractures	
reported,	 171	 fractures	 were	 due	 to	 trauma;	 of	 these	 93	 (54.4%)	 were	 in	 control	
patients	and	78	(45.6%)	in	ZOL	patients.		111	were	non-traumatic	fractures;	of	these	75	
(67.6%)	 were	 in	 the	 control	 arm	 and	 36	 (32.4%)	 in	 the	 ZOL	 arm	 (causality	 was	 not	
specified	 for	 9	 fractures).	 The	 5	 year	 fracture	 rate	 for	 patients	 receiving	 ZOL	 was	
significantly	reduced	to	3.8%	(95%CI	2.9,	4.7%)	compared	with	5.9%	in	the	control	arm	
(95%CI	 4.8,	 7.0%);	 an	 overall	 difference	 in	 the	 proportion	 of	 patients	 experiencing	 a	
fracture	within	5	 years	of	 -2.2%	 (95%CI	 -3.9,	 -0.4%).	 In	 addition,	 time	 to	 first	 fracture	
was	 significantly	 increased	 in	 the	ZOL	arm	compared	 to	 control	 (HR	0.69,	95%CI	0.53,	
0.90	[P=0.0053])	(see	figure	2A).	In	the	multivariate	analysis	(adjusted	for	minimization	
factors)	only	treatment	allocation	was	significantly	associated	with	time	to	first	fracture	
(see	 figure	 3).	 This	 interpretation	 was	 unchanged	 when	 missing	 fracture	 data	 were	
included	as	described	 in	 the	 sensitivity	analysis	 (HR	0.72,	95%CI	0.56,	0.93	 [P=0.012]).	
Fracture	incidence	was	reduced	in	both	oestrogen	(ER)	positive	and	negative	disease	(ER	
positive;	control	9.16%,	ZOL	6.71%,	ER	negative;	control	6.36%,	ZOL	4.35%)		suggesting	
benefit	is	gained	from	ZOL	irrespective	of	the	use	of	endocrine	therapies.	
	
Fractures	and	disease	recurrence	
Fractures	were	recorded	in	relation	to	DFS	events.		207	fractures	occurred	before	or	in	
the	absence	of	a	DFS	event	(111	(54%)	in	the	control	arm	and	96	(46%)	in	the	ZOL	arm)	
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(see	figure	2B).	ZOL	reduced	fractures	compared	to	control	at	recognised	sites	of	major	
osteoporotic	fractures	including	the	femur	(inclusive	of	neck	of	femur)	(0.11%	vs	0.29%),	
wrist	(0.59%	vs	1.25%)	and	spine	(0.23%	vs	0.59%)	(see	table	2).	
80	fractures	occurred	after	a	DFS	event	(59	(73.8%)	in	the	control	arm	and	21	(26.3%)	in	
the	ZOL	arm	(relationship	to	recurrence	was	unknown	in	4)	(see	figure	2C),.	 	 	Adjuvant	
ZOL	reduced	fractures	compared	to	control	after	a	DFS	event	in	the	femur	(inclusive	of	
neck	of	 femur)	 (1.27%	vs	2.03%)	and	spine	 (0.85%	vs	3.04%)	 in	addition	to	other	sites	
such	as	ribs	and	pelvis	(see	table	2).		Of	the	80	fractures	that	occurred	after	a	DFS	event	
the	 majority	 occurred	 in	 patients	 who	 experienced	 a	 skeletal	 recurrence	 (n=60);	 45	
(75%)	 were	 in	 the	 control	 arm	 and	 15	 (25%)	 were	 in	 the	 ZOL	 arm.	 The	 majority	 of	
fracture	 prevention	 benefit	 from	 adjuvant	 ZOL	 appeared	 to	 occur	 after	 a	 disease	
recurrence	event	 (HR	0.30,	95%	CI	0.17,	0.53;	P<0.0001).	 	The	2	year	 fracture	rate	 for	
patients	 in	 the	 ZOL	 arm	 following	 a	 DFS	 event	 was	 substantially	 reduced	 from	 9.8%	
(95%CI	 7.1,	 12.6%)	 in	 the	 control	 arm	 to	 2.8%	 (95%CI	 1.2,	 4.4%),	 with	 an	 absolute	
difference	in	the	proportion	of	patients	in	each	treatment	group	experiencing	a	fracture	
within	2	years	post-disease	recurrence	of	6.1%	(95%CI	9.3,	3.0%).	
	
Fractures	and	menopausal	status	at	study	entry	
166	 patients	 classed	 as	 pre-,	 peri	 or	 unknown	 menopausal	 status	 at	 study	 entry	
experienced	a	 fracture,	98	 (4.23%)	 in	 the	control	arm	and	68	 (2.93%)	 in	 the	ZOL	arm.	
The	most	 common	 sites	 for	 fracture	 in	 this	menopausal	 sub-group	within	 the	 control	
arm	were	the	spine	 (0.82%),	 ribs	 (1.08%)	and	wrist	 (0.73%)	while,	 in	 the	ZOL	arm,	the	
most	common	fracture	sites	were	ribs	(0.6%),	arm	(0.52%)	and	foot	(0.43%).		78	patients	
defined	as	>5	years	postmenopausal	at	study	entry	experienced	a	fracture,	42	(4.03%)	in	
the	control	arm	and	36	(3.46%)	in	the	ZOL	arm.		The	most	common	sites	for	fracture	in	
this	menopausal	sub-group	in	the	control	arm	were	the	femur	(0.96%),	leg	(below	knee)	
(1.05%)	and	arm	(0.77%)	while,	 in	the	ZOL	arm,	the	most	common	fracture	sites	were	
the	 arm	 (0.77%),	 foot	 (0.77%)	 and	 wrist	 (0.58%).	 	 The	 5	 year	 fracture	 rate	 for	 ZOL	
patients	 was	 reduced	 in	 both	menopausal	 groups	 compared	 to	 the	 control	 arm	 (see	
figure	4A),	however,	 the	greatest	 reductions	 in	 fractures	with	ZOL	were	 seen	 in	 the	2	
years	following	a	DFS	event	for	both	menopausal	groups	(see	figure	4B).	
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Menopausal	 status	 did	 not	 significantly	 influence	 the	 benefit	 gained	 in	 fracture	
prevention	with	ZOL,	with	similar	 reductions	 in	 the	overall	population	and	 in	post-DFS	
event	 fracture	 rates	 across	 all	 menopausal	 groups	 (relative	 difference	 in	 the	 HRs	 for	
treatment	(ZOL	vs.	control)	between	menopausal	groups;	overall	HR=0.76,	95%CI	0.427,	
1.33;	P=0.33;	post	DFS	1.72,	95%CI	0.432,	6.855;	P=0.43)	(see	table	3).	
	
	
Skeletal	Toxicity	
26	cases	of	osteonecrosis	of	the	jaw	(ONJ)	were	confirmed	in	patients	treated	with	ZOL	
giving	an	ONJ	rate	of	1.7%	(95%CI	1.1-2.4).		The	majority	of	cases	occurred	whilst	on	or	
within	6	months	of	stopping	study	medication.	No	cases	of	ONJ	were	confirmed	in	the	
control	arm.	No	atypical	femoral	fractures	were	recorded.	
	
Discussion	
These	results	from	the	AZURE	study	show	that	in	a	mixed	menopausal	population,	
adjuvant	ZOL	reduced	the	incidence	and	rate	of	fractures.		Compared	to	standard	
adjuvant	treatment,	both	fracture	incidence	and	time	to	first	fracture	were	significantly	
improved	with	ZOL,	and	the	5-year	fracture	rate	in	patients	receiving	ZOL	reduced	to	a	
rate	that	is	similar	to	that	reported	in	non-breast	cancer	patients	(3.97%	95%CI	3.94,	
3.99)	[18]
.
		The	majority	of	the	benefit	in	fracture	prevention	was	seen	after	disease	
recurrence	in	patients	who	developed	metastases,	especially	at	bony	sites.		At	disease	
recurrence	trial	medication	was	stopped	and	patients	received	treatment	as	per	local	
site	protocol,	including,	where	appropriate,	bone	targeted	treatments,	suggesting	the	
difference	in	fracture	rates	after	disease	recurrence	is	due	to	improvements	in	the	
structural	integrity	of	the	skeleton	by	ZOL	prior	to	disease	recurrence.		
	
The	 limitations	 of	 our	 study	 include	 the	 possible	 under	 ascertainment	 of	 fractures,	
considering	 that	 they	 were	 reported	 as	 part	 of	 skeletal-related	 adverse	 event	 (AE)	
reporting	and	not	actively	monitored	with	serial	 imaging.	 	However	 this	 limitation	will	
have	 likely	 affected	 both	 treatment	 groups	 similarly	 and	 would	 not	 be	 expected	 to	
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change	 the	 overall	 conclusions.	 Symptomatic	 fractures	 that	 result	 in	 AE	 reporting	 are	
also	likely	to	be	of	greater	clinical	significance	than	those	identified	on	serial	imaging.	
	
Adjuvant	 ZOL	has	 been	 shown	 to	 reduce	BMD	 loss	 in	 premenopausal	women	 treated	
with	ovarian	suppression	and	tamoxifen/	anastrazole	 [7],	premenopausal	women	with	
ovarian	failure	due	to	chemotherapy	[19,20]	and	postmenopausal	women	receiving	AIs	
[13,21,22].	 	 In	 these	 bone	 protection	 studies,	 the	 majority	 of	 patients	 received	 a	 6	
monthly	regimen	of	ZOL.	Fracture	rates	were	not	reported	in	most	of	these	studies	but,	
preservation	of	BMD	has	been	shown	to	correlate	with	a	reduced	fracture	risk	[23,24].	
Our	 data	 suggests	 that	 whilst	 adjuvant	 ZOL	 does	 reduce	 fracture	 incidence	 prior	 to	
disease	recurrence,	this	effect	is	perhaps	more	modest	that	was	assumed	from	the	BMD	
studies.	 Bone	 health	 guidelines	 during	 cancer	 therapy	 commonly	 recommend	
assessment	of	fracture	risk	and	treatment	with	bisphosphonates	if	baseline	BMD	T	score	
is	<2.0	or	if	two	or	more	clinical	risk	factors	for	fracture	are	present	[14].	Many	fractures	
occur	 in	 patients	 with	 normal	 BMD	 and	 thus	 both	 patient	monitoring	 and	 treatment	
decisions	should	consider	all	risk	factors	for	fracture.		
	
Recently	the	ABSCG-18	study	has	shown	that	the	addition	of	the	alternative	osteoclast	
inhibitor,	denosumab	60mg	every	6	months,	 in	postmenopausal	women	on	AIs,	halves	
fracture	rates	irrespective	of	baseline	T	score[25]	.	This	study	provides	the	best	evidence	
to	 date	 for	 fracture	 prevention	 in	 early	 breast	 cancer.	 The	 study	 also	 supports	 the	
recommendation	that	selecting	patients	for	treatment	with	osteoclast	inhibitors	on	the	
basis	of	baseline	BMD	or	loss	of	BMD	over	time	may	undertreat	some	patients	at	risk	of	
fracture	 on	 adjuvant	 systemic	 therapy.	 	 The	 rate	 of	 fractures	 in	 the	 placebo	 treated	
patients	within	ABCSG-18	was	higher	than	that	seen	in	our	study	(9.6%	95%CI	8.0,	11.2	
at	 36	 months),	 which	 is	 unsurprising	 considering	 that	 AZURE	 recruited	 a	 lower	 risk	
population	by	including	both	pre	and	postmenopausal	women	and	included	those	with	
oestrogen	receptor	positive	or	negative	tumours,	thereby	resulting	in	limited	use	of	AIs.		
	
In	our	study	the	predominant	fracture	prevention	benefit	of	adjuvant	ZOL	after	disease	
recurrence,	when	the	majority	of	patients	will	be	established	on	bone	targeted	agents	
for	skeletal	recurrence	irrespective	of	adjuvant	treatment,	is	of	interest.		Zoledronic	acid	
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is	 known	 to	 have	 long	 term	 effects	 on	 bone	 metabolism	 years	 after	 treatment	 has	
ceased	 [26]	 which	may	 improve	 the	 resilience	 of	 bone	 in	 the	 presence	 of	metastatic	
disease.	 In	 ABCSG-18	 the	 effects	 of	 denosumab	 on	 fractures	 occurring	 after	 disease	
recurrence	were	not	 specifically	 reported,	although	a	 sensitivity	analysis	with	patients	
censored	at	the	time	of	disease	recurrence	did	not	change	the	overall	results,	suggesting	
that	 the	 predominant	 benefit	 from	 adjuvant	 denosumab	 is	 on	 the	 prevention	 of	
adjuvant	 treatment	 related	 fractures.	 	 Denosumab’s	 short	 half-life	 in	 bone	 compared	
with	a	bisphosphonate	may	limit	effects	on	skeletal	morbidity	after	disease	recurrence.	
This	 shorter	 duration	 of	 action	 of	 denosumab	 is	 reflected	 by	 reports	 of	 increased	
fracture	rates	on	cessation	of	the	drug	in	the	osteoporosis	setting	[27].		
	
The	1.7%	incidence	of	ONJ	in	AZURE	patients	receiving	ZOL	needs	to	be	considered.		The	
ONJ	rate	in	AZURE	is	higher	than	was	identified	in	studies	of	ZOL	administered	every	six	
months	 (ABCSG-12,	ZOFAST,	Z-FAST	and	EZO-FAST)	 in	which	only	2	 cases	of	ONJ	have	
been	 reported	 in	 over	 4000	 patients	 [28].	 This	 probably	 reflects	 the	 more	 intense	
schedule	 ZOL	 used	 in	 the	 first	 6	months	 of	 the	AZURE	 study.	Of	 note,	 there	were	 no	
cases	 of	 ONJ	 identified	 in	 the	 ABCSG-18	 study	 [25]	 and	 therefore	 risk	 vs	 benefit	 of	
treatment	favours	denosumab	in	postmenopausal	women	for	fracture	prevention	alone,	
whereas	 in	 higher	 risk	 patients	 in	 whom	 disease	 recurrence	 prevention	 is	 a	 priority,	
adjuvant	 BPs	 can	 reduce	 breast	 cancer	mortality	 [17]	 in	 addition	 to	 reducing	 fracture	
risk,	which	offsets	the	small	risk	of	ONJ.		
	
The	 recently	 published	 large	 meta-analysis	 of	 randomised	 trials	 of	 adjuvant	
bisphosphonates	 demonstrated	 the	 reduction	 in	 breast	 cancer	 recurrence	 rates	 and	
breast	cancer	mortality	in	postmenopausal	women	[17].	However,	whether	denosumab	
also	 has	 this	 effect	 is	 not	 yet	 known.	 	 In	 the	 ABSCG-18	 study,	 Gnant	 and	 colleagues	
reported	 fewer	DFS	 events	 in	 patients	 treated	with	 denosumab	 (n=167)	 compared	 to	
placebo	(n=203),	equivalent	to	an	18%	reduced	risk	of	recurrence	at	a	median	follow	up	
of	4	years[29].	However,	the	study	was	unblinded	and	patients	offered	active	treatment	
from	2016,	so	reliable	longer	follow-up	information/survival	data	from	this	trial	may	not	
become	 available.	 The	 role	 of	 adjuvant	 denosumab	 on	 disease	 recurrence	 is	 being	
formally	evaluated	in	the	D-CARE	study	(NCT01077154)	which,	like	AZURE,	randomised	a	
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broad	 range	 of	 patients	 at	 high	 risk	 of	 recurrence;	 results	 from	 this	 study	 will	 be	
available	 in	 2018.	 Until	 then,	 the	 role	 of	 adjuvant	 denosumab	 should	 be	 limited	 to	
fracture	prevention	in	women	at	low	risk	for	breast	cancer	recurrence	and,	as	suggested	
by	 clinical	 guidelines	 [30]	 should	 not	 be	 prioritized	 over	 the	 use	 of	 an	 adjuvant	
bisphosphonate.	
	
Adjuvant	 bisphosphonates	 have	 now	 become	 the	 standard	 of	 care	 for	 many	
postmenopausal	women	to	reduce	bone	recurrence	and	improve	breast	cancer	survival.	
Our	study,	in	addition	to	identifying	the	disease	recurrence	benefits	of	adjuvant	ZOL	in	
postmenopausal	women	with	early	breast	cancer,	has	shown	a	modest	added	benefit	of	
a	reduction	 in	 fracture	rates,	 further	strengthening	the	role	of	bisphosphonates	 in	the	
adjuvant	setting.	
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Figure	legends	
	
Figure	1.	Consort	diagram	trial	profile.		
Note	that	more	than	1	reason	was	given	for	some	patients	not	receiving	allocated	
zoledronic	acid.	
	
Figure	2	Cumulative	incidence	function	curve	of	time	to	first	fracture	by	randomized	
treatment,	Overall	(A)	,	before	disease	recurrence	(B)	and	after	disease	recurrence	(C).		
(In	A,	19	patients	had	missing	fracture	dates	and	in	B	1	patient	in	the	ZOL	arm	had	a	
missing	fracture	date.	These	patients	were	censored	at	the	last	date	known	to	be	alive	
without	any	fractures).		
	
Figure	3:	Forest	plot	based	on	hazard	ratios	for	factors	included	in	the	multivariate	
analysis	of	time	to	first	fracture.	Error	bars	are	95%CIs	
	
Figure	4.	Interactions	between	menopausal	status,	treatment	allocation	and	frequency	
of	clinical	fractures		
A.	Overall	5	year	fracture	rates	in	patients	treated	with	standard	therapy	(control)	and	
standard	therapy	plus	zoledronic	acid	(ZOL)	according	to	menopausal	status.	Error	bars	
are	95%	CIs.	Hazard	ratios	for	time	to	first	fracture	according	to	menopausal	status	are	
0.45-0.88	for	pre,	peri,	unknown	menopausal	group	and	0.52-1.33	for	>5	years	
postmenopausal.	
B	2	year	fracture	rates	post	DFS	event	in	patients	treated	with	standard	therapy	alone	
(control)	and	standard	therapy	plus	zoledronic	acid	(ZOL)	according	to	menopausal	
status.	Error	bars	are	95%	CIs.	Hazard	ratios	for	time	to	first	fracture	post	DFS	event	
according	to	menopausal	status	are	0.21-0.71	for	pre,	peri,	unknown	menopausal	group	
and	0.06-0.75	for	>5	years	postmenopausal.	
	
